B+
Bull case
25%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
DCGO
DocGoANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.42
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.16
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+88.9
Score
AI commentary
Recent coverage is mixed: record core volumes, the Hicuity transaction, committed financing and conference participation are constructive, while widened loss guidance, cash consumption and transaction risk remain negative. No sufficient social dataset, options-skew reading, short-interest figure or dependable post-Q2 analyst-revision evidence was supplied; zero values in those fields indicate unavailable inputs rather than neutral readings. Low coverage and the $0.3652 micro-cap share price warrant a cautious monitoring stance [#SEC-8K-2026-08-17].
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventHicuity acquisition and financing executionHigh impact
DocGo announced a definitive agreement to acquire Hicuity Health alongside a new Perceptive Advisors term-loan commitment. Closing certainty, financing terms, leverage and integration expectations could produce an outsized move in this micro-cap equity, while delays or adverse terms would increase downside risk [#SEC-8K-2026-08-17].
2026-12-31catalystCore-volume growth versus margin and cash validationHigh impact
Q2 revenue declined to $73.4 million as migrant-program revenue fell to zero, but revenue excluding those programs grew 19% year over year, medical transportation revenue reached $52.0 million, and non-migrant Mobile Health revenue grew 78%. A sustained core-growth trajectory accompanied by improved margins and lower cash consumption would support a re-rating; another weak conversion quarter would undermine it [#SEC-8K-2026-08-17].
2027-06-30catalystConversion of non-migrant growth into sustainable profitabilityHigh impact
Record activity across transportation, home health, mobile phlebotomy, monitoring and virtual-care orders provides an operating-growth base, but Q2 adjusted EBITDA remained negative and unrestricted cash declined to $25.2 million. The long-term catalyst is evidence that scale and cost controls can restore positive profitability without materially dilutive financing [#SEC-8K-2026-08-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology